Linde PLC vs Medtronic PLC — how do they compare? Linde PLC trades at $483.73 (market cap $222.05B), while Medtronic PLC trades at $88.48 (market cap $112.24B). The key difference: Linde PLC is the larger of the two by market cap, and Medtronic PLC pays the higher dividend (3.28%). Which is the better fit depends on your goals — on Pluang, investors hold Linde PLC for 88 Days and Medtronic PLC for 63 Days on average.
| LIN | MDT | |
|---|---|---|
Market Cap | $222.05B | $112.24B |
Volume | 2,116,440 | 105,663,236 |
Sector | Basic Materials | Health |
52-Week High | $546.64 | $105.35 |
52-Week Low | $389.38 | $73.75 |
Typical Hold Time | 88 Days | 63 Days |
Enterprise Value | $245.17B | $131.58B |
Dividend Yield | 1.33% | 3.28% |
Signals from Pluang's Aura AI — not financial advice
Linde (LIN) trades at $481.70, down 0.47% on the day, with strong technical momentum showing a bullish moving average signal. The company demonstrates robust fundamentals with consistent earnings beats, including Q2 2026 EPS of $4.50 beating estimates of $4.49, and maintains healthy profitability with a 20.43% net income margin. Analyst sentiment remains overwhelmingly positive with 89.66% buy ratings and a $557.10 consensus price target representing 15.6% upside potential from current levels.
The outlook remains favorable given Linde's leadership in industrial gases and exposure to AI chip manufacturing growth, though valuation at 31.08 P/E requires continued execution. Key risks include margin pressure from higher capital expenditures and competitive dynamics in the electronics sector. The stock's technical setup suggests support near $479 with resistance at $485, providing clear levels for near-term price action.
Medtronic (MDT) trades at $87.75, up 2.62% today, with strong analyst support (60.8% buy ratings) and a $97.80 consensus price target suggesting 11.5% upside. The stock shows consistent earnings beats in recent quarters and maintains a 49-year dividend growth streak. However, technical indicators signal bearish momentum with resistance near $89-90. Revenue growth accelerated to $33.54B in 2025 with net margins improving to 13.93%, though debt levels have risen to 31.1% of assets.
MDT presents a compelling value opportunity with attractive dividend yield and earnings momentum, but faces near-term technical headwinds and increasing leverage. The upcoming Q3 earnings report and MiniMed separation will be critical catalysts. Investors should weigh the strong fundamental recovery against bearish technical signals and monitor debt management closely.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →